NMC
PRQR icon

Nine Masts Capital’s ProQR Therapeutics PRQR Stock Holding History

Nine Masts Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,518
Closed -$47.8K – 269
2026
Q1 		$47.8K Buy
+29,518
New +$48.4K 0.01% 144

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Nine Masts Capital's PRQR Position: Q2 2026 in Review

Nine Masts Capital sold out of ProQR Therapeutics (PRQR) in Q2 2026, closing a stake of 29,518 shares — an estimated $47.8K sold.

Nine Masts Capital first reported a position in PRQR in Q1 2026 and held it in 1 quarter. The position peaked at $47.8K in Q1 2026. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Nine Masts Capital reported no remaining ProQR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 29,518 ProQR Therapeutics shares in Q2 2026, an estimated $47.8K.
  • Nine Masts Capital first reported a position in ProQR Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's ProQR Therapeutics position peaked at $47.8K in Q1 2026.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.